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Summary
Background: Gemcitabine (GEM) and paclitaxel (TAX) are
active, non-cross-resistant drugs in non-small-cell lung cancer
(NSCLC). We performed a phase I study to determine the
maximum-tolerated dose (MTD), antitumor activity and phar-
macokinetics of GEM and TAX given weekly in chemo-nai've
patients with advanced NSCLC.
Patients and methods: Escalating doses of GEM (800-2000
mg/m2) and TAX (60-100 mg/m2) were administered on days
1, 8, 15 every 4 weeks to 35 patients with advanced NSCLC.
Plasma pharmacokinetics of TAX and GEM was assessed at
the three higher dose-levels.
Results: Dose-escalation was discontinued in absence of
MTD because of increased cumulative toxicity leading to dose
modification or treatment delay at levels 6 and 7 (TAX 100
mg/m2 plus GEM 1750 and, respectively, 2000 mg/m2). Hem-
atological toxicity included grade 4 neutropenia in 3% of
cycles, grade 3 thrombocytopenia in one cycle and febrile
neutropenia in three cycles. Maximal non-hemathological tox-
icity was grade 3 elevation in serum transaminases and grade 2
neuro-sensory toxicity in 8% and 5% of cycles, respectively. At
the two higher dose-levels a non-linear pharmacokinetics of
GEM was observed with a remarkable variability of Cm a x and
AUC. No pharmacokinetic interactions were reported. Objec-
tives responses were seen at all dose levels, with an overall
response rate of 43% (95% confidence interval (95% CI):
25.5%-62.6%) in 30 evaluable patients.
Conclusions: The weekly administration of GEM and TAX is
very well tolerated, and has shown promising antitumor activity
in NSCLC. In view of the cumulative toxicity and of the pharma-
cokinetic profile of GEM, doses of 1500 mg/m2 of GEM and
100 mg/m2 of TAX are recommended for phase II studies.
Key words: gemcitabine, non-small-cell lung cancer, paclitaxel,
pharmacokinetic
Introduction
Chemotherapy has been shown to improve both quality
of life and survival in patients with advanced non-small-
cell lung cancer (NSCLC) [1, 2].
Paclitaxel (TAX) and Gemcitabine (GEM) are both
active as single agent in NSCLC with acceptable toxicity
profiles. Cumulative data from several studies with TAX
in advanced NSCLC patients showed a median response
rate of about 25%, with a one-year survival rate of 41%
[3]. A weekly schedule of TAX appeared active and well
tolerated resulting in a higher dose-intensity and frequent
exposure to the drug. The MTD in chemo-nai've patients
was reached at 175 mg/mq/w for six weeks of an eight-
week cycle, with acute dose-limiting neutropenia and
cumulative peripheral neuropathy [4, 5].
The pharmacokinetic profile of one-hour infusion
of TAX has been shown to be comparable to that of
three-hour infusion with higher peak plasma levels, but
similar toxicity and activity and no increase of hyper-
sensitivity reactions in spite of the simplified regimen of
prophylaxis adopted [6-10].
GEM is considered an active agent in NSCLC, with a
cumulative response rate of 21% and a one-year survival
of 39% among 572 patients [3]. The most extensively
used regimen is the weekly 30-minute infusion for three
consecutive weeks every four weeks.
The rationale of combining GEM and TAX for
NSCLC is provided by their antitumor activity, different
mechanism of cytotoxicity and different toxicity profiles.
Three phase I—II studies of TAX plus GEM combina-
tions have been performed on a total of one hundred
both chemo-naive and pretreated patients with advanced
NSCLC [11-13], with an overall response rate of 29%-
42%. In these studies TAX was administered every three
weeks with escalation of the dose from 90 mg/m2 to 240
mg/m2 in two of them.
Only preliminary data in a still ongoing study with a
weekly administration of GEM and TAX in patients
with different solid tumors are available [14]. In the
present study we wanted to evaluate the toxicity and
antitumor activity of TAX and GEM given weekly as
initial treatment in NSCLC patients. Pharmacokinetic
and pharmacodynamic evaluations of GEM and TAX
were performed at the higher dose levels.
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Patients and methods
Eligibility criteria
Chemo-nai've patients with histologically or cytologically proven stage
Illb-IV NSCLC were eligible for this study. Additional eligibility
criteria were adequate bone marrow (WBC ^35OO/ul and platelet
count > 100,000/ul), hepatic (AST, ALT ^ 2 times and total bilirubin
$ 1.25 times upper limits of normal) and renal (serum creatinine
$ 1.25 times upper limits of normal) functions, 18-65 years of age,
performance status (ECOG) $2, >3 months of life expectancy,
written informed consent. Exclusion criteria were a prior radiotherapy
to more than 30% of bone marrow reserve, absolute contraindication
to steroids, previous or concurrent malignancies, uncontrolled infec-
tions. The protocol was approved by the local ethical committee.
Pretreatment evaluation
Pretreatment evaluation included complete history and physical exami-
nation, complete blood cell count, a full chemistry profile, ECG, chest
X-ray and CT scan, abdomen CT scan or ultrasound and bone scan.
During treatment a weekly complete blood cell count and a complete
chemistry profile on the first day of each treatment were performed.
Treatment schedule, toxicity and response evaluation
The dose-escalation schedule is listed in Table 2. TAX and GEM were
administered weekly on an outpatient basis for three consecutive weeks
every 28 days. TAX was administered as a one-hour i.v. infusion after
prophylactic premedication with prednisone 25 mg orally 12 hours and
hydrocortisone 200 mg plus ranitidine 100 mg plus clorfenamine 10 mg
i.v. 1 hour before treatment.
GEM was administered immediately after TAX as a 30-minute i.v.
infusion. One cycle of treatment consisted of three consecutive weekly
administrations of TAX and GEM followed by one week of rest.
All patients with measurable disease underwent complete tumor-
response assessment after two cycles. WHO response criteria were used
[15]. Four to eight cycles were planned according to physician's discre-
tion in both responders and in patients with stable-disease.
Toxicity was evaluated according to WHO criteria.
Treatment was repeated on day 28 if absolute neutrophils (ANC)
and platelets were > 1.5 x 103/ul and 5= 100 x 103/ul, respectively, and
in presence of non-hematological toxicity $G1 (hepatic toxicity
^ G2). Otherwise, treatment was delayed for one week and, if these
conditions were still not satisfied on day 35, discontinued and toxicity
considered to be dose-limiting. Treatment administration was given
on day 8 and 15 if ANC and platelets were > 1,0 x l03/ul and
> 75 x 10/ul, respectively, with non-hematological toxicity <G2
(excluding nausea/vomiting and alopecia). Otherwise, treatment was
discontinued and toxicity considered to-be dose-limiting.
Quality of life was assessed weekly by the EORTC QLQ-C30 and
LC-13. We used a linear mixed effect model to investigate if the quality
of life scores were the same over time to take into account the repeated
observations on each subject [16], We permitted the intercept and slope
to vary according to each subject. The within subject correlation
matrix was taken to be the identity matrix as there was no evidence of
any serial correlation in the within subject residuals over time.
Dose finding procedures and DLT
At each dose level three patients, six in case of dose-limiting toxicity
(DLT) were entered. The maximum tolerated dose (MTD) was defined
as the dose level at which DLT was observed in two out of three or in
three out of six patients during the first cycle. DLTs were an ANC of
<0.5 x 103/ul lasting >7 days, febrile neutropenia (fever > 38.5 °C
with G4 neutropenia or febrile G3 neutropenia requiring i.v. anti-
biotics or hospitalization); platelets <25 x 103/ul, neurotoxicity
> G2, mucositis > G2; treatment withheld because of toxicity on days
8 or 15 or a treatment delay of > 1 week on day 28.
Dose intensity
Dose intensity (DI) (mg/m2/wk) was calculated by the following
formula: total milligrams of drug per body surface areas/total days of
therapy/7, where total days is the number of days between day one of
the first cycle and day 28 of the last one.
Pharmacokinetic and pharmacodynamic analysis
Pharmacological evaluations were performed on patients treated with
GEM at 1500, 1750 and 2000 mg/m2 in association with TAX 100 mg/
m2. Blood samples were drawn from the arm not receiving the infusion
before treatment (baseline), 15 minutes and 1 hour after the start of
TAX infusion, 5 and 30 minutes after the start of GEM infusion and
5, 15, 30 minutes and 1, 2, 4, 12, 24 hours after it. Samples were
centrifuged for 10 minutes at 3,500 g and stored at -20 °C. Plasma
levels of TAX, GEM and its metabolite 2',2'-difluorodeoxyuridine
(dFdU) were determined by a high performance liquid chromato-
graphic assay previously described [17, 18]. Pharmacokinetic analysis
was performed by a Kinfit module incorporated in the MW/PHARM
computer program [19] (Mediware, Groningen, The Netherlands) and
drug disposition was fitted to an open two compartment linear model.
The area under the plasma concentration-time curve (AUC) was
calculated using a combination of the linear and log trapezoidal rules
extrapolated to infinity. The pharmacokinetic study of TAX included
the measurement on individual plasma concentration-time plots of the
time spent above the threshold level of 0.05 umol/1 (tCOOs) [20].
Pharmacodynamic correlations between the percentage decrease in
absolute leucocyte, neutrophil and platelet count defined as: 100 x
(pre-treatment value - nadir value)/pre-treatment value and Cmax and
AUC of TAX and GEM, and time of plasma concentrations above
0.05 umol/1 of TAX were assessed. These relationships were fitted to
sigmoidal maximum effect (Emax) models [21] using nonlinear least
squares regression and a weighting factor of unity (GraphPad Prism,
GraphPad Software, USA).
Pharmacokinetic differences were analyzed by the unpaired /-test
[22].
Results
Patient characteristics
Between November 1997 and March 1999, 35 consecutive
patients entered the study (Table 1). All patients were
assessable for toxicity and 30 for response because of
lack of measurable disease in 5.
Dose levels and toxicity
The doses of GEM and TAX were escalated from 800 to
2000 mg/m2 and from 60 to 100 mg/m2, respectively,
through 7 dose levels; a total of 143 treatment cycles
were administered, 111 of them at full dose, all evaluable
for toxicity (Table 2).
DLT, hematological, and hepatic toxicity
A total of six DLTs, all hematological, were registered,
five of which at the three highest dose levels. DLTs during
the first cycle consisted of G3 and G2 thrombocyto-
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Table 1. Patients' characteristics (« = 35).
Characteristic
Age (years)
Median
Range
Sex
Male
Female
Performance status (ECOG)
0-1
Stage
IIIB
IV
Prior radiation
Histology
Adenocarcinoma
Large cell
Squamous cell
Poorly diff. ca
Main sites of disease
Lung
Liver
Brain
Bone
Number of patients
54
36-73
22
13
35
2
33
7
19
3
7
6
33
8
6
16
Table 2. DLT at first cycles and reasons of treatment delay or dose-
modifications over all 143 cycles.
Dose GEM
level (mg/
m2)
TAX
(mg/
m2)
No.
of
pts
Dose limiting
toxicity («)
Reason of delay or
modification (n)
all cycles
800 60
800
1000
1000
1500
80
80
100
100
1750 100
2000 100
G3 thrombocyto-
peniaday 15 (1)
G2 thrombocyto-
penia day 15(1)
Neutropenic
fever (1)
Neutropenic fever
(2)
G4 neutropenia
day 15(1)
Taxol allergic
reaction (1)
Pneumonitis (1)
Transaminitis (1)
Neurotoxicity (1)
Herpes zoster (1)
Neurotoxicity (1)
Neurotoxicity (2)
Transaminitis (1)
Taxol allergic
reaction (1)
Transaminitis (2)
Neurotoxicity (1)
Astenia(l)
penia on day 15, with recovery within a week, in one of
six and in one of seven patients, treated at dose level 3
and 5, respectively, of neutropenic fever requiring i.v.
antibiotics in a different patient treated at the dose level
5, in two of six patients at dose level 6, and of G4
neutropenia on day 15, with recovery within a week, in
one of six patients at dose level 7. The main reason for
treatment delay or modification of the dose was cumu-
lative neurotoxicity (five patients) and hepatotoxicity
(four patients). Hepatic toxicity was limited to elevations
in serum transaminases, always asymptomatic and re-
versible.
Table 3 reports the incidence of grade 3—4 neutro-
thrombocytopenia and elevation in serum transaminases
during the first and all cycles.
Neutropenia was dose-dependent: all G4 neutropenia
episodes but one occurred at dose levels 6 and 7, where a
16% and 10%, respectively, of incidence of G3-G4
neutropenia among all cycles was registered. Grade 3
thrombocytopenia occurred in only one case at dose
level 3. Elevation of hepatic transaminases occurred at
all levels but the first but it was not either dose-dependent
or cumulative. It was G2 in 50%-100% of patients at all
levels and G3 in 20% of cycles at the highest dose level.
At this dose, however, two of six patients were retreated
at dose level 6 because of elevation of hepatic trans-
aminases.
Other non-hematological toxicities
Other non-hematological toxicity, including nausea and
vomiting, mucositis, diarrhea and neuro-sensory pe-
ripheral neuropathy, were always mild to moderate and
non-cumulative; they were not clearly dose-dependent
but were more frequent at the highest dose level (Table 4),
at which two patients were retreated at the lower
dose of GEM because of asthenia and, respectively,
neurotoxicity. Neurotoxicity consisted in extremities
paresthesias and/or dysesthesia, always reversible after
treatment interruption.
Complete alopecia occurred in six patients, three of
whom at dose level 7.
Transient flu-like syndrome consisting of low-grade
fever, myalgias and fatigue, was reported in seven
patients. It was responsive to acetaminophen and not
dose dependent.
Two allergic reactions was registered, one of them
with dyspnoea and bronchospasm, requiring treatment
interruption. The same reaction was observed when the
patient received cisplatin plus GEM.
Quality of life
For the EORTC QLQ-C30 there was no evidence of any
trend in the scores (P = 0.5). There was evidence that
the LC-13 scores increased within subject over time
(P = 0.01). The increase is estimated at 0.3 (95% CI:
0.08-0.53) points per week. Patients whose treatment
terminated early tended to have a high LC-13 score
prior to ceasing treatment. Patients who remained on
treatment for more than eight administrations tended to
have low LC-13 scores throughout the treatment period.
Dose-intensity
The results of the analysis of the delivered dose intensity,
of both drugs over all cycles of treatment are summar-
ized in Table 5.
According to this analysis, which takes into account
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Table 3. First cycles and overall grade 3-4 hematological toxicity and elevation of hepatic transaminases.
Level
1
2
3
4
5
6
7
7aWe 4.
Level
1
2
3
4
5
6
7
Other
Number of
patients/cycles
3/7
4/17
6/21
3/10
7/23
6/13
6/20
non-hematological
Number
of
patients/
cycles
3/7
4/17
6/21
3/10
7/23
6/13
6/20
Cycles
with
nausea/
vomiting
(/")
1 2
57 14
29 0
24 0
30 0
48 0
15 8
25 20
Percentage of cycles with
neutropenia
First
(#7 = :
3
0
25
0
0
14
17
17
toxicity.
Cycles
withi
mucositis
(%)
1
0
0
19
20
4
23
25
2
0
6
0
10
39
23
35
'5)
4
0
0
0
0
0
17
17
Cycles
with
neuro-
sensory
1
0
6
0
10
39
23
35
">
0
0
0
10
8
8
10
All
(#7=111)
3
0
29
5
10
43
8
5
4
0
0
5
0
0
8
5
Cycles
with
diarrhea
(%)
1
0
18
9
20
0
8
5
2
0
0
0
10
0
0
0
Tablt
Percentage of cycles with
thrombocytopenia
First
(»
3
0
0
17
0
0
0
0
;5 .
= 35)
4
0
0
0
0
0
0
0
Scheduled vs.
All
(#7 = 1
3
0
0
5
0
0
0
0
111)
4
0
0
0
0
0
0
0
delivered percent
and gemcitabine over all cycles.
Dose
level
1
2
3
4
5
6
7
Scheduled
GEM-TAX
dose
(mg/mq)
800-60
800 80
1000-80
1000-100
1500-100
1750-100
2000-100
Delivered
GEM
(% dose)
93
98
96
98
86
88
90
Percentage of cycles with
elevation of hepatic trans-
aminases
Firsl
(#7 =
3
0
0
33
0
0
0
33
dose
Delivered
TAX
(% dose)
93
98
96
96
91
79
89
: All
35) (#7 = 111)
4 3 4
0 0 0
0 0 0
0 19 0
0 0 0
0 0 0
0 0 0
0 20 0
intensity for paclitaxel
Delivered GEM
and TAX cumulative
% dose over all the
cycles of therapy
93
98
96
97
88
83
89
the dose reductions for each drug as well as any delays in
drug administration, the actual dose intensities of TAX
and GEM delivered were lower than 85% only for dose
level 6.
The average dose intensity administered was higher
for dose levels from 1 to 5 (94.5%) than for dose levels 6
and 7 (86.4%), due to the more frequent dose reductions
and dose delays due to toxicity.
Pharmacokinetic and pharmacodynamic analysis
In patients given GEM 1500, 1750 and 2000 mg/ra2, the
mean Cmax values of TAX at the end of infusion were
9.10 ± 2.27, 8.96 ± 1.28 and 8.94 ± 4.09 umol/1. Plasma
concentrations decreased in the post-infusion period by
a bi-exponential decay with comparable pharmaco-
kinetic profiles at the three dose levels of GEM. The
TAX AUC at the three different dose levels were also
comparable, with concomitant total clearance values of
7.61 ± 1.81, 8.25 ± 2.97 and 8.57 ± 2.62 1/h/m2, thus
indicating that dose-escalation of GEM did not affect
TAX disposition.
Peak plasma levels of GEM were reached at the end
of infusion and increased from 18.56 ± 2.85 to 40.85 ±
14.85 and the AUC values increased from 9.99 ± 1.59 to
25.01 ± 9.87 ug/ml/h from 1500 to 2000 mg/m2. Ac-
cording to these results, increasing the dose of GEM by
17% and 33% from 1500 mg/m2 resulted in a mean
increase of 27% and 120% of Cmax and of 32% and
150% of AUC. These data suggest a saturable kinetics
of GEM within the dose range administered. This ob-
servation is also supported by the observed significant
decrease of the total clearance of GEM for doses of
1500 mg/m2 and, respectively, 2000 mg/m2 of 160.4 ±
22.0 1/h/m2 and 92.5 ± 38.9 1/h/m2.
Accordingly, the pharmacokinetics of dFdU was lin-
early related to the dose of GEM with Cmax values of
63.2 ± 9.7, 70.6 ± 19.0 and 79.7 ± 15.3 ug/ml and AUC of
159.9 ± 46.2, 182.0 ± 49.0 and 224.9 ± 61.5 ug/ml/h at
1500,1750 and 2000 mg/m2 dose levels, respectively.
The analysis of the correlation between pharmaco-
kinetics and drug effect demonstrated that percentage
decrease in ANC was related to the time of exposure to
TAX concentrations ^0.05 umol/1, as described by the
sigmoid maximum effect (Emax) pharmacodynamic
model (r2 = 0.63). The comparison with historical data
[20] indicated that the duration of plasma concentra-
tions above the threshold value of TAX 0.05 umol/1
predicted to yield a 50% reduction in ANC were 10.4
hours and, approximately, 17 hours in patients treated
with TAX-GEM and TAX alone, respectively. This
suggests that patients receiving TAX and GEM experi-
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Table 6. Pharmacokinetic parameters (mean ± SD) of TAX, GEM and dFdU.
Parameter TAX GEM dFdU
Gemcitabine dose
(mg/m2)
Paclitaxel dose (mg/m2
Cmax
AUCb
)
1500
100
9.10 ±2.27
13.86 + 4.07
1750
100
8.96 ± 1 28
14.45 + 2.03
2000
100
8.94 ± 4.09
12.73 + 4 22
1500
100
18.56 ± 2
9 9 9 + 1
.85
59
1750
100
23.56 ± 4.08
13 21 + 2 20
2000
100
40.85
25 01
± 14.85
+ 9 87
1500
100
63.2 ±9.7
159.9 ±46.2
1750
100
70.6 ± 19.0
182.0 ±49.0
2000
100
79.7
224.9
±15.3
±61.5
' Cm M: TAX - |imol/l; GEM and dFdU - jig/ml.
' AUC: TAX - nmol/l/h; GEM and dFdU - ng/ml/h.
Table 7. Antitumor activity.
Level
1
2
3
4
5
6
7
All
a
 95% CI:
Number of
assessable
patients
3
4
4
3
5
6
5
30
25.5-62.6.
CR
0
0
0
0
0
0
0
0
PR
2
3
1
0
2
2
3
13
SD
0
0
0
1
1
1
2
5
PD
1
1
3
2
2
3
0
12
RR
(%)
67
75
25
_
40
33
60
43a
enced more neutropenia than would be expected from
TAX alone.
In the analysis of the relationship between haemato-
logical toxicity and pharmacokinetics of GEM only the
percentage decrease in platelets appeared to be related
to the Cmax of GEM through sigmoid Emax pharmaco-
dynamic model relationship (r2 = 0.76). The sigmoid
curve of Cmax and percentage decrease in platelets
reached a plateau for a percentage decrease in platelets
of 58.7% (95% CI: 46.3%-71.1%).
Antitumor activity
Antitumor activity was evaluated in all 30 patients with
measurable disease treated with at least 2 cycles of che-
motherapy (Table 7). Responses were seen at all dose
levels, with no clear evidence of a dose-response rela-
tionship. Thirteen out of thirty assessable patients (43%;
95% CI: 25.5%-62.6%) achieved a partial response, five
had stable disease and twelve had disease-progressions.
Median time to progression was 15.8 weeks (range 6.7-
56 weeks).
A median of 5 courses (range 2-6) were given to
responding patients, with response noted after a median
of 2 courses (range 2-6).
Discussion
We performed a dose-finding study to define the
maximal tolerated dose (MTD) of gemcitabine (GEM)
and paclitaxel (TAX) given weekly for three consecutive
weeks followed by one-week rest in chemo-naive pa-
tients with advanced NSCLC. Seven dose-levels were
evaluated, with TAX dose escalated from 60 mg/m2
to 100 mg/m2/w and GEM from 800 mg/m2 to 2000
mg/m2/w.
Dose escalation was discontinued after doses of TAX
and GEM of 100 mg/m2 and, respectively, 2000 mg/m2
because four out of six patients treated at this dose-level
had neurotoxicity, asthenia or hepatotoxicity requiring a
decrease of GEM dose to dose level 6 and three patients
developed G3 transaminitis. Consequently, even though
the criteria of MTD were not satisfied because only one
patient treated at the higher level experienced a DLT
(G4 neutropenia in day 15), the study was closed and
weekly doses of 100 mg/m2 TAX and 1500 mg/m2 GEM
were proposed for further clinical evaluation.
The main DLT was myelosuppression, with G2—3
thrombocytopenia on day 15 in 2 patients, G4 neutro-
penia on day 15 in 1 patient and neutropenic fever requir-
ing i.v. antibiotics in 3 patients out of 35 patients treated.
Fourteen patients had treatment delays or modifications
due to non-hematological toxicities, namely neurotoxicity
in five patients and transaminitis in four patients.
The patients compliance to this schedule was excellent.
Grade 2 alopecia occurred in 14% of patients while the
only G3 non-hematological toxicity consisted of asymp-
tomatic reversible rising of transaminases (8% of cycles).
Two allergic reactions were registered, one of them with
dyspnea and asthmatic phenomena requiring treatment
interruption. Grade 2 neuro-sensory toxicity occurred in
6 out of 35 patients and it was always reversible.
The analysis of the quality of life data supports the
view that this regimem is well tolerated, with stable
trends in QLQ-C30 scores.
In the present study GEM displayed a linear phar-
macokinetics up to 1500 mg/m2, after which a non-linear
pharmacokinetic behavior and a higher interpatient
variability of Cmax and AUC were reported.
The pharmacokinetics achieved in the present study
indicate that TAX disposition is not affected by GEM
administered at doses between 1500 and 2000 mg/m2
as suggested by the comparison with previous results
achieved with TAX single agent [23, 24]. The present
data confirm he results of Kroep et al. of no interactions
between GEM and TAX in patients receiving fixed
doses of both drugs given intermittently on a three-week
schedule [25].
Percentage decrease in platelets appeared to be related
to Cmax of GEM (r2 - 0.76) and the highest percentage
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decrease of 58.7% was achieved for a GEM Cmax of 18|ig/ml, after which a further increase of Cmax did not
result in a higher percentage decrease in platelets.
In the present study, thrombocytopenia was of lower
degree as compared to the one observed in a phase I of
GEM with 50% of patients experiencing nadir platelet
values of less than 50,000 cells/mm3 at 1000 mg/m2/w
[17]. Thrombocytopenia was not observed also on pa-
tients treated with single agent TAX 100 mg/m2/h [23],
and a positive pharmacodynamic interaction between
TAX and GEM might be considered. However the lack
of cellular pharmacology of dFdCTP, the cellular Cmax
of which was shown to be affected in a dose-dependent
manner by TAX [25] do not allow a more extensive
comparison with other TAX and GEM studies.
Overall the pharmacokinetic results suggest an in-
creasing risk of possible unpredictable side-effects at the
higher treatments levels, consistent with the cumulative
toxicity and the higher number of patients requiring
treatment modification at dose levels 6 and 7.
Major responses were observed at all the treatment
levels with 13 partial responses (overall response 43%,
95% CI: 25.5%-62.6%), 5 stable disease and 12 disease
progression among the 30 evaluable patients. Median
time to progression was 15.8 weeks (range 6.7-56 weeks).
The lack of dose-response relationship and of linearity
of GEM pharmacokinetics at the higher doses were addi-
tional rationale to decide discontinuing dose escalation.
Although TAX is not rarely administered at 200-250
mg/m2, its dose-response relationship is still matter of
debate and advantages of administering doses higher
than 125-150 mg/m2 every three weeks have not been
conclusively proven [26, 27]. Also for GEM a clear dose-
response relationship for weekly doses higher than 900-
1250 mg/m2 is still unproved [28-34].
The favorable toxicity profile and the promising anti-
tumor activity reported in the present study in chemo-
naive patients with NSCLC support further clinical
evaluation of GEM and TAX given in combination at
1500 mg/m2 and, respectively, 100 mg/m2 weekly, for
three consecutive weeks.
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